The US Food and Drug Administration has now issued a green light for the use of AstraZeneca’s diabetes combination therapy Qtern to treat patients with type II diabetes, having rejected it back in 2015 with a request for more clinical data.
Read More
Adults in the UK with type II diabetes have gained a new treatment option to keep blood sugar levels under control with the launch of AstraZeneca’s Qtern in the country.
Read More
The European Commission has green-lighted Qtern (saxagliptin/dapagliflozin) for the treatment of type II diabetes in all 28 EU member countries plus Iceland, Liechtenstein and Norway.
Read More
